Metabolomics and Target Heterogeneity in Radioligand Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 4446
Special Issue Editors
Interests: theranostic; precision oncology; neuroendocrine tumor; prostate cancer; PET/CT; PET/MRI
Special Issue Information
Dear Colleagues,
The success of two prospective randomized clinical trials in neuroendocrine tumor (NETTER-1) and prostate cancer (VISION) have finally proven the real potential of radioligand therapy (RLT). No wonder several phase 1–3 studies are now exploring the utility of RLT in other tumor entities and in different stages of tumor evolution. Apart from investigating treatment efficacy, tolerability, and adverse effects in controlled clinical trials, it is equally imperative to understand the basic mechanism(s) of action of the powerful radioligands, as not all patients respond well to RLT. One of the primary prerequisites for achieving a sufficient radiation dose in and around the tumor cells is the density of target expression on the tumor lesions. Indeed, different clones of tumor cells within tumor lesions are the primary driving force in regulating the expression of targets and determining their radiation sensitivity. For both neuroendocrine tumors as well as prostate cancer patients treated with radioligands, apart from the metabolism, e.g., glucose metabolism or serotonin metabolism, single-center retrospective clinical data as well as preclinical studies have shown predictive and prognostic values of receptor heterogeneity and shown promise in exploring the metabolic pathways to determine the inherent radiation sensitivity of tumor cells.
This Special Issue will focus on the integration of several heterogeneity parameters stemming from imaging and molecular markers to enhance and integrate research and researchers in the field of tumor heterogeneity and metabolomics. The final aims are to increase the efficacy of RLT via a) the selection of appropriate patients, b) a decreased treatment-related toxicity, and c) optimized sequence of treatment options.
Dr. Vikas Prasad
Dr. Nat P. Lenzo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radioligand therapy
- tumor heterogeneity
- receptor heterogeneity
- serum biomarkers
- molecular pathology
- pharmacogenomics
